登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式(希尔记法):
C21H24FN3O4· HCl
化学文摘社编号:
分子量:
437.89
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352200
MDL number:
Beilstein/REAXYS Number:
8377447
产品名称
莫西沙星 盐酸盐, 98-102% (HPLC)
InChI key
IDIIJJHBXUESQI-DFIJPDEKSA-N
SMILES string
Cl.COc1c(N2C[C@@H]3CCCN[C@@H]3C2)c(F)cc4C(=O)C(=CN(C5CC5)c14)C(O)=O
InChI
1S/C21H24FN3O4.ClH/c1-29-20-17-13(19(26)14(21(27)28)9-25(17)12-4-5-12)7-15(22)18(20)24-8-11-3-2-6-23-16(11)10-24;/h7,9,11-12,16,23H,2-6,8,10H2,1H3,(H,27,28);1H/t11-,16+;/m0./s1
assay
98-102% (HPLC)
form
powder
storage condition
desiccated
color
light yellow to yellow
solubility
H2O: slightly soluble
storage temp.
−20°C
Quality Level
正在寻找类似产品? 访问 产品对比指南
Application
盐酸莫西沙星已被用于研究其对已生长至高密度细菌的抗菌作用。
Biochem/physiol Actions
莫西沙星已被证明可有效治疗鼻窦炎、社区获得性呼吸道感染、肺炎和慢性支气管炎的急性加重。与其他氟喹诺酮(如环丙沙星和氧氟沙星)相比,它具有更好的抗革兰氏阳性活性。莫西沙星可用于治疗细菌性皮肤感染。它可以适当渗透到周围组织和炎性液体中。氟喹诺酮类可通过与酶-DNA复合物结合来稳定由DNA回旋酶和拓扑异构酶IV产生的DNA链断裂。 与哺乳动物DNA促旋酶相比,莫西沙星对细菌DNA促旋酶的亲和力高100倍。莫西沙星是一种抗生素,可抗革兰氏阳性和革兰氏阴性细菌。莫西沙星在治疗耐多药结核病中的研究正在进行中。
General description
莫西沙星是第四代合成氟喹诺酮类抗菌剂。莫西沙星与其他喹诺酮类药物不同,其是一种8-甲氧基喹诺酮。
signalword
Warning
hcodes
Hazard Classifications
Acute Tox. 4 Oral - Aquatic Chronic 3 - Eye Irrit. 2
存储类别
11 - Combustible Solids
wgk
WGK 2
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
涉药品监管产品
此项目有
An HPLC Method for the Determination of Moxifloxacin in Breast Milk by Fluorimetric Detection with Precolumn Derivatization.
Tekkeli SEK
Acta Chromatographica , 10-10 (2016)
Understanding and sensitizing density-dependent persistence to quinolone antibiotics.
Gutierrez A, et al.
Molecular Cell, 68(6), 1147-1154 (2017)
Ana Topete et al.
Journal of controlled release : official journal of the Controlled Release Society, 326, 245-255 (2020-07-20)
Posterior capsule opacification (PCO) still remains the most frequent long term complication after cataract surgery, while endophthalmitis is rare but severe and should be prevented at all cost. Intraocular lenses (IOLs) with different designs (eg. edge and body-haptics angle) and
Edward D Chan et al.
American journal of respiratory and critical care medicine, 169(10), 1103-1109 (2004-01-27)
Multidrug-resistant tuberculosis, a disease caused by Mycobacterium tuberculosis strains that are resistant at least to rifampin and isoniazid, entails extended treatment, expensive and toxic regimens, and higher rates of treatment failure and death. We retrospectively analyzed the outcomes in 205
Stephen H Gillespie
European respiratory review : an official journal of the European Respiratory Society, 25(139), 19-28 (2016-03-02)
Tuberculosis (TB) remains a global threat with more than 9 million new infections. Treatment remains difficult and there has been no change in the duration of the standard regimen since the early 1980s. Moreover, many patients are unable to tolerate
我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持